These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 361222)

  • 1. Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-(m-AMSA) using a single-dose schedule.
    Von Hoff DD; Howser K; Gormley P; Bender RA; Glaubiger D; Levine AS; Young RC
    Cancer Treat Rep; 1978 Oct; 62(10):1421-6. PubMed ID: 361222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical and pharmacological study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide using an intermittent biweekly schedule.
    Van Echo DA; Chiuten DF; Gormley PE; Lichtenfeld JL; Scoltock M; Wiernik PH
    Cancer Res; 1979 Oct; 39(10):3881-4. PubMed ID: 476624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 clinical investigation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative.
    Legha SS; Gutterman JU; Hall SW; Benjamin RS; Burgess MA; Valdivieso M; Bodey GP
    Cancer Res; 1978 Nov; 38(11 Pt 1):3712-6. PubMed ID: 279397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) by a weekly iv dose schedule.
    Woodcock TM; Schneider RJ; Young CW
    Cancer Treat Rep; 1980 Jan; 64(1):53-5. PubMed ID: 6892893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of triglycidylurazol given on a 5-day i.v. schedule.
    Nicaise C; Rozencweig M; Crespeigne N; Dodion P; Gerard B; Lambert M; Decoster G; Kenis Y
    Cancer Treat Rep; 1986 May; 70(5):599-603. PubMed ID: 3708609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of chlorozotocin.
    Gralla RJ; Tan CT; Young CW
    Cancer Treat Rep; 1979 Jan; 63(1):17-20. PubMed ID: 154363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
    Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
    Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
    Alberts DS; Mackel C; Pocelinko R; Salmon SE
    Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of maytansine using a 3-day schedule.
    Cabanillas F; Rodriguez V; Hall SW; Burgess MA; Bodey GP; Freireich EJ
    Cancer Treat Rep; 1978 Mar; 62(3):425-8. PubMed ID: 348310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
    LoRusso P; Foster BJ; Poplin E; McCormick J; Kraut M; Flaherty L; Heilbrun LK; Valdivieso M; Baker L
    Clin Cancer Res; 1995 Dec; 1(12):1487-93. PubMed ID: 9815948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of 4'-(9-acridinylamino) methanesulfon-m- anisidide (AMSA) in metastatic melanoma.
    Legha SS; Hall SW; Powell KC; Burgess MA; Benjamin RS; Gutterman JU; Bodey GP
    Cancer Clin Trials; 1980; 3(2):111-4. PubMed ID: 6893573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of SOAz.
    Nasca S; Jezekova D; Coninx P; Garbe E; Carpentier Y; Cattan A
    Cancer Treat Rep; 1982 Dec; 66(12):2039-42. PubMed ID: 7139646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Phase I-II studies of a new antineoplastic agent, 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA)].
    Horikoshi N; Ogawa M; Inagaki J; Ezaki K; Inoue K; Okabe K; Nagata T; Aiba K; Domyo M
    Gan To Kagaku Ryoho; 1982 Feb; 9(2):244-9. PubMed ID: 6897858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272).
    Surbone A; Ford H; Kelley JA; Ben-Baruch N; Thomas RV; Fine R; Cowan KH
    Cancer Res; 1990 Feb; 50(4):1220-5. PubMed ID: 1688736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I-II study of m-AMSA administered as a continuous infusion.
    Micetich KC; Zwelling LA; Gormley P; Young RC
    Cancer Treat Rep; 1982 Oct; 66(10):1813-7. PubMed ID: 6897013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of mitoxantrone by 24-hour continuous infusion.
    Anderson KC; Garnick MB; Meshad MW; Cohen GI; Pegg WJ; Frei E; Israel M; Modest E; Canellos GP
    Cancer Treat Rep; 1983 May; 67(5):435-8. PubMed ID: 6850662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Phase I study of CI-898. CI-898 Study Group].
    Taguchi T; Tsukagoshi S; Furue H; Niitani H; Ohta K; Ariyoshi H; Hasegawa K; Majima H; Nakao I; Yasutomi M
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1599-612. PubMed ID: 1831340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
    Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
    Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).
    Judson IR; Calvert AH; Rutty CJ; Abel G; Gumbrell LA; Graham MA; Evans BD; Wilman DE; Ashley SE; Cairnduff F
    Cancer Res; 1989 Oct; 49(19):5475-9. PubMed ID: 2670205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.